Cerus Corporation — Third Quarter 2026 Earnings Summary

Cerus Corporation reported third-quarter 2026 total revenue of $64.0 million, driven by a 10% year-over-year increase in product revenue to $57.7 million. The company announced positive topline results from the Phase 3 RedeS trial for its INTERCEPT Blood System for red blood cells and achieved approximately 80% growth in INTERCEPT Fibrinogen Complex volumes. Operating cash flow for the quarter was $3.0 million, bringing the total cash, cash equivalents, and short-term investments to $57.1 million as of September 30, 2026. Cerus reiterated its full-year 2026 product revenue guidance of $229 million to $231 million, reflecting expected growth of 11% to 12%.